Sepsis is defined as life‐threatening organ dysfunction caused by a deregulated immune host response to infection. The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has highlighted this multifactorial and complex syndrome. The absence of specific treatment neither against SARS‐CoV‐2 nor against acute respiratory distress syndrome (ARDS), the most serious stage of this infection, has emphasized the need to find alternative treatments. Several therapeutics are currently being tested, including mesenchymal stromal cells. These cells, already used in preclinical models of ARDS, sepsis, and septic shock and also in a few clinical trials, appear well‐tolerated and promising, but many questions remain unanswered.

中文翻译：

---

间充质基质细胞用于败血症和败血性休克：治疗COVID-19的课程。

败血症的定义是由于免疫宿主对感染的反应失调导致的威胁生命的器官功能障碍。严重急性呼吸系统综合症冠状病毒2（SARS-CoV-2）的出现突出了这种多因素和复杂的综合症。既没有针对SARS-CoV-2的特殊治疗，也没有针对这种感染最严重阶段的急性呼吸窘迫综合症（ARDS）的缺乏，强调了寻找替代治疗的必要性。目前正在测试几种治疗剂，包括间充质基质细胞。这些细胞已经在ARDS，败血症和败血性休克的临床前模型中使用，并且已经在一些临床试验中使用，它们的耐受性良好且很有希望，但仍有许多问题尚未得到解答。